Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCARLET: Shorter Chemo-Immunotherapy in Early TNBC
NCT05929768Phase 3Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Sep 2023
- Primary completion
- Mar 2033
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of docetaxel, carboplatin, pembrolizumab in triple-negative breast cancer (TNBC), sponsored by SWOG Cancer Research Network. Started Sep 2023; status: recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05929768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05929768.